![Jennifer Champoux](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jennifer Champoux
Direttore operativo presso MONTE ROSA THERAPEUTICS, INC.
Patrimonio netto: 711 428 $ in data 30/06/2024
Posizioni attive di Jennifer Champoux
Società | Posizione | Inizio | Fine |
---|---|---|---|
MONTE ROSA THERAPEUTICS, INC. | Direttore operativo | 01/03/2021 | - |
Ufficiale delle Risorse Umane | 01/03/2021 | 28/05/2024 |
Storia della carriera di Jennifer Champoux
Precedenti posizioni note di Jennifer Champoux
Società | Posizione | Inizio | Fine |
---|---|---|---|
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Corporate Officer/Principal | - | - |
Formazione di Jennifer Champoux
Indiana University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 4 |
Posizioni
Chief Operating Officer | 1 |
Human Resources Officer | 1 |
Corporate Officer/Principal | 1 |
Settori
Health Technology | 3 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
MONTE ROSA THERAPEUTICS, INC. | Health Technology |
Aziende private | 1 |
---|---|
H3 Biomedicine, Inc.
![]() H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
- Borsa valori
- Insiders
- Jennifer Champoux
- Esperienza